Clinical trial
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV)…
NCT00411645 · Shire, Industry · Completed
Key facts
| NCT number | NCT00411645 |
|---|---|
| Title | Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients |
| Official title | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants. |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Infections |
| Intervention type | Drug, Other |
| Interventions | maribavir, placebo |
| Enrollment | 681 |
| Start date | Dec 13, 2006 |
| Primary completion | Nov 10, 2008 |
| Completion | May 23, 2009 |
| First posted | Dec 14, 2006 |
| Last update posted | Jun 11, 2021 |
| Countries | Belgium, Canada, France, Germany, Italy, Spain, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: